This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Becton Dickinson (BDX) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Becton Dickinson (BDX) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Boston Scientific Expects Strong Gains in 2025: Time to Buy the Stock?
by Urmimala Biswas
Boston Scientific begins 2025 on a solid note, expecting organic revenue growth of 14% to 16% in the first quarter.
Do Options Traders Know Something About BD (BDX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to BD (BDX) stock based on the movements in the options market lately.
ABT Stock Jumps 12% Since Q4 Earnings: Time to Invest in Abbott?
by Urmimala Biswas
Abbott projects organic sales growth between 7.5% and 8.5% for 2025.
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BD Stock Falls in Pre-Market Despite Q1 Earnings Beat, Gross Margin Up
by Zacks Equity Research
BDX's overall topline in the first quarter of fiscal 2025 continues to benefit from revenue growth in all segments.
Compared to Estimates, Becton Dickinson (BDX) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Becton Dickinson (BDX) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 15.10% and 1.32%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of -0.12% and 0.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Can Sustained Product Demand Drive BDX Stock Before Q1 Earnings?
by Zacks Equity Research
The continued solid uptake of BD's products is expected to have driven fiscal first-quarter revenues despite transitory market dynamics.
Insights Into Becton Dickinson (BDX) Q1: Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Becton Dickinson (BDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Becton Dickinson (BDX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic's Q1 Earnings Coming Up: How to Play the Stock?
by Moumi Mondal
In the first quarter of fiscal 2025, HOLX is expected to have benefited from the strength of its core franchises.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BD Stock Rises on Biosero Deal for AI-Powered Robotic Cytometry Tech
by Zacks Equity Research
BD and Biosero collaborate to integrate robotic automation with flow cytometry technology, aiming to accelerate drug discovery.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BDX or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BDX vs. MMSI: Which Stock Is the Better Value Option?
BLS Data Shows Slowdown in Core CPI: Time to Buy MDT Stock Now?
by Urmimala Biswas
Medtronic's strong liquidity position should allow it to meet its near-term debt obligations.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH